ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QDEL
ACHV (39) MYGN (47) NNNN (35) NTLA (25) ⌘ Pro Terminal →

QuidelOrtho Corporation (QDEL) — RQD Stock Rating Cockpit

$14.03 +5.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.15

QuidelOrtho Corporation (QDEL) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $908.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QDEL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QDEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, QuidelOrtho Corporation (NASDAQ: QDEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $14.03 (+5.89% 1D, market cap $908.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QDEL ranks #965 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QDEL compare to ACHV and MYGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QDEL carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $702.8M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QDEL?
▼

Per QDEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0001906324), QuidelOrtho Corporation generated $2.73B in revenue (-1.9% YoY), -$1.13B in net income, and -$83.0M in free cash flow against $5.77B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.15 (+0.87%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510021
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (3)Whales (7)SEC (6)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.7% Base Target
$37 Bull$12 Base$9 Bear
📬 FREE QDEL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QDEL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (21/100 Composite)
🔍 WHY QDEL SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+7/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (29% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$14.10+0.8% Next Q
Q2 (-2Q)
26
Grade E$14.21-4.4% Next Q
Q3 (-1Q)
24
Grade E$13.59+3.2% Next Q
Current
21
Grade E$14.03-11.6% Hist 90D α
Trajectory: E (29) → E (21)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QDEL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QDEL currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.71) and Max Pain ($14.73) forces dealer call-delta covering toward $37.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QDEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QDEL Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”
YES 21%NO 79%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
50.630 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE16% OF RANGE
L: $10$14.03H: $36
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 2 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 9 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on QDEL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-35.0% ROIC with 42.0% gross margin and -8.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (30)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

10/40 institutional & smart-money positioning score with 3/20 macro alignment.

Bull Case: Why Buyers Like QDEL
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QDEL)

  • ✓Walkthrough of QDEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QDEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.96%⚡ TESTING RESISTANCE
2026-11-03O $13.76H $14.03L $13.25C $14.03VOL 1.74M
RES: $14.45SUP: $9.03SMA50: $12.71SMA200: $16.05
$25.76$21.46$17.17$12.88$8.59RES $14.45SUP $9.03$14.032026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QDEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QDEL Butterfly Map → + Track QDEL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QDEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QDEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QDEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QDEL)

Health Care Rank #965 of 1015 ⚔️ ACHV vs QDEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QDEL vs. ACHV, MYGN, NNNN, NTLA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, QuidelOrtho Corporation (QDEL) ranks #965 by composite RQD confidence (21/100, grade E) and #370 by equity capitalization ($908.6M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. MYGN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with QDEL at 21/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QDEL ACTIVE
QuidelOrtho Corporation
E 21/100 — — -35.0% +5.89% $908.6M Benchmark Subject
ACHV
Achieve Life Sciences Inc.
D- 39/100 — — -35.0% -3.22% $702.8M /achv-vs-qdel →
MYGN
Myriad Genetics Inc.
D 47/100 — 69.9% -35.0% -7.87% $607.4M /mygn-vs-qdel →
NNNN
Anbio Biotechnology (Class A)
D- 35/100 83.6x 87.2% 17.0% +4.46% $483.5M /nnnn-vs-qdel →
NTLA
Intellia Therapeutics Inc.
E 25/100 — — -35.0% -6.50% $1.75B /ntla-vs-qdel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0001906324 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-28), QuidelOrtho Corporation (QDEL) reported GAAP revenue of $2.73B (-1.9% vs. FY2024 revenue of $2.78B , and -8.9% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of $105.2M, and free cash flow of -$83.0M (+26.0% YoY). On the balance sheet, QDEL closed FY2025 with $5.77B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-28 $2.73B -$1.13B $105.2M -$83.0M $5.77B —
FY2024 (FY) 2024-12-29 $2.78B -$2.05B $83.0M -$112.1M $6.42B —
FY2023 (FY) 2023-12-31 $3.00B -$10.1M $280.2M $280.2M — —

3. QDEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QDEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, QuidelOrtho Corporation (NASDAQ: QDEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $14.03 (+5.89% 1D, market cap $908.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 6/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QDEL ranks #965 in composite RQD confidence.

How does QDEL compare to ACHV and MYGN in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QDEL carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $702.8M) and MYGN (Myriad Genetics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $607.4M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QDEL?

Per QDEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0001906324), QuidelOrtho Corporation generated $2.73B in revenue (-1.9% YoY), -$1.13B in net income, and -$83.0M in free cash flow against $5.77B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QDEL trading relative to its 50-day, 200-day, and 52-week technical levels?

QDEL last traded at $14.03 (+5.89% on volume of 2,857,712 shares), positioning the stock +10.39% above its 50-day simple moving average ($12.71) and -12.59% below its 200-day simple moving average ($16.05). Across its 52-week range of $9.92 to $35.58, QDEL sits at the 16.0% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.28 to $15.78).

Direct Sub-Reports: QDEL RQD Cockpit QDEL 12M Forecast QDEL Earnings & Move QDEL Dividends & DRIP QDEL Insiders & 13F QDEL Whale Options QDEL Profit Sankey QDEL News & Why
ROARABLE RATING BRIEF • RQD 21/100 (E) ✓ SEC XBRL & RQD VERIFIED

QDEL — QuidelOrtho Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-28

1. Roarable Rating Brief: What This Means to a Prospective Investor

QuidelOrtho Corporation (QDEL) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $14.03 (+5.89% 1D, market capitalization $908.6M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -33.7%, and free cash flow yield of -8.80%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (6/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

QuidelOrtho Corporation (QDEL) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The profile identifies the company as a diagnostics participant with a market capitalization of $0.9B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-28), QuidelOrtho Corporation (QDEL) reported $2.73B in annual revenue (up from $2.78B in FY2024, -1.9% YoY) and -$1.13B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.00B revenue, -$10.1M net income) through FY2025, QDEL scaled operating cash flow to $105.2M and free cash flow to -$83.0M, backed by $5.77B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 21/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -8.80% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $9.92 – $35.58 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -33.7% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream dependencies, downstream customers, and sector correlations beyond the Health Care sector classification are not identified in the source data.

  • Key Question #1: Can QDEL sustain or expand its -33.7% operating margin and -35.0% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.73B and free cash flow of -$83.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is QDEL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QDEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for QuidelOrtho Corporation (QDEL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QDEL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QDEL Bull vs. Bear Conversation Board — What's Your Call at $14.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QDEL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QDEL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $15.50 (+17.0%)
📌 Pinned Debate

Institutional whale 13F flow scores 9/20, the strongest pillar, indicating accumulation and options positioning that is more constructi

The street is overcomplicating QuidelOrtho Corporation (QDEL). Institutional whale 13F flow scores 9/20, the strongest pillar, indicating accumulation and options positioning that is more constructive than the fundamentals.. With an RQD score of 21/100 (E) and Forensic Balance Sheet at 6/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $14.31.

EarningsSniper 🐂 BULL

Both sides have a point here — QDEL's 6/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $10.20 (-23.0%)
Spot @ $13.25

ROIC of -35%, FCF yield of -8.8%, and an Altman Z-Score of 0.2 show the business is destroying capital and sits in a distressed forensi

ROIC of -35%, FCF yield of -8.8%, and an Altman Z-Score of 0.2 show the business is destroying capital and sits in a distressed forensic range.. Look at the math on QDEL: paying current EV/EBITDA multiples for -35.0% ROIC and -33.7% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $11.66 before getting long.

LIVE TAPE